Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

Background Oral treatment options for disease-modifying therapy in relapsing multiple
sclerosis have substantially increased over the past decade with four approved oral …

Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …

Background: Moderate and high efficacy disease modifying therapies (DMTs) have a
profound effect on disease activity. The current treatment guidelines only recommend high …

Background SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute
respiratory distress syndrome (ARDS), which can cause significant mortality, leading to …

Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B
cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared …

Background and Objectives To evaluate the rate of return of disease activity after cessation
of multiple sclerosis (MS) disease-modifying therapy. Methods This was a retrospective …

Dimethyl fumarate (Tecfidera®) is approved for the treatment of relapsing forms of multiple
sclerosis (MS). Based on evidence from the clinical trial and real-world settings, dimethyl …

Background: We conducted this study to estimated the time of conversion from relapsing-
remitting MS (RRMS) to SPMS and its early predictor factors. Methods: In this retrospective …

Importance As disease-modifying treatment options for multiple sclerosis increase,
comparisons of the options based on real-world evidence may guide clinical decision …